Cytel is the world’s leading data-science CRO, driving advancements in human health through robust analytics and innovative clinical trial software. For nearly four decades, we have set the standard in adaptive trial design, leveraging extensive data insights to inform strategy throughout every phase of drug development and commercialization. Our mission is clear: accelerate drug development, enhance success rates, and deliver better patient outcomes. With a comprehensive suite of services from innovative trial design to end-to-end biometrics and real-world evidence, our specialized, multidisciplinary team ensures optimal strategies for preclinical research, trial execution, market access, and reimbursement. Headquartered in Cambridge, Massachusetts, Cytel has a global presence with over 2,000 employees across North America, Europe, and Asia. Learn more about how Cytel is harnessing the power of data to advance human health at www.cytel.com.
Cytel的外部链接
In our of our most recent blogs with Ann-Kristin Spiik, we dove deeper into the topic of oligotherapeutics, one of the most promising and exciting pharmaceutical development, especially for rare diseases. How many ASO therapies for different rare diseases have received FDA or EMA approval up to now? If you don’t know and want a hint, best to check out our blog again on https://lnkd.in/gAt7b_sU ??
此处无法显示此内容
在领英 APP 中访问此内容等
For our last webinar of the year we're looking at the future: how will open-source programming like R impact clinical trials? Join Corey Dunham and various other experts on December 12 for an insightful online roundtable! Register here: https://hubs.ly/Q02Z8qxD0 #SAS #OpenSource
The clinical research landscape is evolving rapidly, and the FDA's latest guidance on integrating real-world clinical trials (RCTs) into clinical practice is a game-changer. As the potential of Real-World Evidence (RWE) grows, understanding these developments is essential to staying ahead. Join Massoud Toussi and Yannis Jemiai for The Evidence Base Office Hours as we unpack the key implications of this new guidance and explore how it could shape your work in clinical trials. Register here: https://hubs.ly/Q02Z0Tv30 #FDA #RWE #RealWorldEvidence
And that's almost a wrap for ISPOR 2024! Many thanks to all who joined us at the booth or at our 35+ (!) speaking sessions and our HEOR theater, with a full house attendance at almost all of them! Thank you for the amazing insights and conversations! See you next year! If you weren't able to attend but want to connect, reach out to us: https://hubs.ly/Q02YWcH90 #ISPOR #RWE #HEOR
The Cytel team will be present at PHUSE India SDE this week! Don't miss Diganta Bose's presentation Evolving Around Impacts of Automating Statistical Programming Tasks" while you're there! Meet up with the Cytel team there and discover how we're empowering life science leaders to realize the full potential of their therapies! #PHUSE #CDISC
Read the post: https://hubs.ly/Q02YGzsv0 Oligonucleotide #therapeutics are an emerging modality being developed to treat ultra #rarediseases. Ann-Kristin Spiik shares her experience and discusses what’s on the horizon for this promising area of #pharmaceutical development. #biotech #pharma #clinicaldevelopment #drugdevelopment #drug #patients #clinicaltrials #regulatoryaffairs
After a great day 1 at ISPOR Europe 2024, the Cytel team is ready for day 2! Special congratulations to our colleague Massoud Toussi as this year's winner of the "Recognition of service to society" award! Make sure to stop by booth 1500 and discover how we are helping life science leaders realize the full potential of their therapies! #ISPOR #HEOR #RWE #RWA #MarketAccess
Today, we’re excited to welcome Heather Jones as Cytel’s new Chief Human Resources Officer! Heather brings a wealth of knowledge in talent strategy, employee engagement, organizational development, and international HR leadership, with a strong emphasis on fostering deep business partnerships. At Cytel, we are committed to creating an environment where our people can thrive and innovate, and Heather’s expertise will be invaluable in driving initiatives that support our mission and strengthen our culture. Welcome to the team, Heather! Read more: https://hubs.ly/Q02Ywbk60
HTA typically involves SLRs to form the #evidence base from which reimbursement decisions are made. But the volume of info and potential for overlap with other sponsors can cause issues. Vicki Y. shares a solution and new precedent for #HTA submissions. Read the post: https://lnkd.in/eGKbYv4Z Vicki will be at #ISPOR Europe in Barcelona! “Re-using and Sharing Systematic Review #Data Between Competing Companies and HTA Stakeholders: Is It Feasible and How Can Challenges Be Overcome?” Wednesday, Nov. 20, at 10 a.m. We hope to see you there! #biotech #pharma #clinicaldevelopment #regulatoryaffairs #software